Oga inhibitor compounds

A compound of Formula (I)

• or a tautomer or a stereoisomeric form thereof, wherein
• R1 is selected from the group consisting of C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, —CN, —OC1-3alkyl, —OH, —SO2NR5aR6a, and C3-6cycloalkyl optionally substituted with one or more independently selected halo substituents;
• C1-6alkyl substituted with oxetanyl;
• and C1-6alkyl wherein two geminal hydrogens are replaced by oxetanylidene;
• wherein R5a and R6a are each independently selected from the group consisting of hydrogen and C1-3alkyl;
• with the proviso that a —OC1-3alkyl or —OH substituent, when present, is at least two carbon atoms away from the nitrogen atom of the 1H-pyrrolo[3.2-c]pyridine;
• R2, R3 and R5 are each independently selected from the group consisting of hydrogen, halo and C1-3alkyl;
• R4 is a monovalent radical selected from the group consisting of (a), (b), (c), and (d):
• wherein
• R1a, R2a, R1b, and R2b are each independently selected from the group consisting of halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, C1-3alkyloxy, monohaloC1-3alkyloxy, polyhaloC1-3alkyloxy, and C3-6cycloalkyl;
• R3a is selected from the group consisting of hydrogen, halo, —C(O)—OC1-3alkyl, —C(O)—NR′R″, and —N(R′″)—C(O)—C1-3alkyl;
• R4a is selected from the group consisting of hydrogen, halo, —CN, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, —C(O)—OC1-3alkyl, —C(O)—NR′R″, —N(R′″)—C(O)—C1-3alkyl, and Het;
• with the proviso that R3a and R4a are not simultaneously —C(O)—OC1-3alkyl, —C(O)—NR′R″, or —N(R′″)—C(O)—C1-3alkyl;
• R′ and R″ are each independently selected from the group consisting of hydrogen and C1-3alkyl;
• or R′ and R″ together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;
• R′″ is selected from the group consisting of hydrogen and C1-3alkyl;
• Het is pyrazolyl or imidazolyl, optionally substituted with one or more independently selected C1-3alkyl substituents;
• X1 and X2 are each independently selected from N and CH, with the proviso that at least one of X1 or X2 is N;
• R1c, R2c, and R1d are each independently selected from the group consisting of halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, C1-3alkyloxy, monohaloC1-3alkyloxy, polyhaloC1-3alkyloxy, and C3-6cycloalkyl;
• X3 represents CH or N;
• and each of the rings represented by
• form
• (i) a 5- or 6-membered unsaturated heterocycle having one, two or three heteroatoms each independently selected from nitrogen and oxygen, and which is optionally substituted with one or more substituents, each independently selected from halo, C1-3alkyl and oxo;
• or
• (ii) an aromatic heterocycle having one, two or three heteroatoms each independently selected from nitrogen, oxygen, and sulfur, and which is optionally substituted with one or more substituents, each independently selected from halo, —CN, C1-3alkyl, monohaloC1-3alkyl, and polyhaloC1-3alkyl;
• or a pharmaceutically acceptable addition salt or a solvate thereof.